- Some people with colorectal cancer have a genetic mutation causing them to have an MMR deficient/MSI-High tumor.
- Past research shows that treating MMR deficient/MSI-High colorectal cancer tumors can sometimes be difficult.
- A new clinical trial has found that giving the immunotherapy drug pembrolizumab before surgery instead of chemotherapy can help improve outcomes for people with stage two or three MMR deficient/MSI-High colorectal cancer
Written by Corrie Pelc on June 6, 2024 — Fact checked by Jill Seladi-Schulman, Ph.D.
Call us at (888)-243-6602 to discuss how we can help keep your loved one safe and happy at home.